Abstract 344P
Background
Breast cancer imposes a significant regional and global health burden not only due to being the most prevalent malignancy in females in the Middle East and worldwide, but due to the associated substantial morbidity and mortality. Therefore, the determination of the epidemiological features of breast cancer in the Middle East is of prominent interest given the significant resultant burden associated with breast cancer as it enables for the efficient introduction of effective interventions.
Methods
Data on 20,046 female patients of different nationalities and residing in Jordan diagnosed with breast cancer during the period of 2000-2018 were obtained from the Jordan Cancer Registry. Consequently, comprehensive statistical analysis was performed to establish the epidemiological characteristics of breast cancer in Jordan, including the overall survival and crude incidence.
Results
A total of 20,046 female patients with a mean age of 51.5 ± 12.5 years old were included in the analysis. Only 6.54% of the enrolled patients were smokers at the time of diagnosis. Breast cancer was more commonly affecting the left breast, 46.9% of the patients, than the right breast, 43.5% of the patients, whereas 1.18% of the patients had breast cancer bilaterally. The upper outer quadrant of the breast was the most commonly reported site of tumour location. Moderately differentiated carcinoma was the most commonly encountered grade in 31.4% of the patients, whereas 28.9% had poorly differentiated carcinoma. Regional spread to the lymph nodes was observed in 19.0% of the sample and 13.1% of the patients had distant metastasis, while localized breast cancer was noted in 16.6% of the patients. A statistically significant increase in the crude incidence of breast cancer in females has been observed in Jordan over the 18 years period with a crude incidence estimated effect of 0.46 (P-value<0.001). The overall survival rate was determined to be 95.8%, 83.2%, and 62.8% at 1-year, 3-year, and 5-year interval, respectively.
Conclusions
Breast cancer in Jordan imposes a significant burden due to the significant increase in the crude incidence over the 18-year period, and thus mandating vigorous and vigilant screening and preventative measures.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
403P - Breast cancer specific survival (BCSS) in HR+/HER2- metastatic breast cancer (mBC) from 2010 to 2019
Presenter: Adam Brufsky
Session: Poster session 03
404P - A multicenter, single-arm, open-label trial of birociclib, a CDK4/6 inhibitor, as a single agent, in patients with refractory HR+/HER2- metastatic breast cancer
Presenter: Jiayu Wang
Session: Poster session 03
405P - E7389-LF as a first-line (1L) chemotherapy for patients (pts) with metastatic/advanced HER2-negative breast cancer (HER2− BC): Results from a phase I study dose-expansion part
Presenter: Kan Yonemori
Session: Poster session 03
406P - Phase Ib safety and efficacy of nadunolimab/gemcitabine/carboplatin in mTNBC
Presenter: Sara Lopez-Tarruella Cobo
Session: Poster session 03
407P - Palbociclib plus endocrine therapy in HR+/HER2- advanced breast cancer patients: Interim results of the PERFORM study
Presenter: Julia C. Radosa
Session: Poster session 03
408P - Proxalutamide plus endocrine therapy as a combination therapy in women with HR+/HER2-/AR+ metastatic breast cancer: A phase I study
Presenter: Huiping Li
Session: Poster session 03
410P - Patients treated with pertuzumab followed by T-DM1 for breast cancer in France from 2014 to 2021: A survival analysis of 10,408 patients from the French National Hospital discharge summary database (PMSI)
Presenter: Josephine Lemaitre
Session: Poster session 03
411P - Therapy management and safety of 1st-line ribociclib (RIB) + aromatase inhibitor (AI)/fulvestrant (FUL) in clinical routine: Real-world data from the RIBANNA study (5th interim analysis (IA))
Presenter: Frederik Marmé
Session: Poster session 03
412P - Sacituzumab govitecan versus chemotherapy for metastatic breast cancer: A meta-analysis on safety outcomes
Presenter: Alessandro Rizzo
Session: Poster session 03